Anusandhanvallari
Vol 2025, No.1
December 2025
ISSN 2229-3388

Neuroinflammation and Its Role in Alzheimer's Disease from Molecular Mechanisms to Therapeutic Targets

Dr.T.Deborah paripuranam

Assistant Professor

Nadar Saraswathi College of Arts and Science,Theni

Email: debovermi@gmail.com

Abstract: Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by cognitive decline, synaptic failure, and extensive neuronal loss. Growing evidence identifies neuroinflammation as a central and active participant in the pathophysiology of AD rather than a secondary response to amyloid-β (Aβ) accumulation or tau hyperphosphorylation. Persistent activation of microglia, astrocytes, and peripheral immune cells promotes a pro-inflammatory milieu that accelerates Aβ deposition, enhances tau pathology, disrupts neuronal signaling, and compromises neurovascular function. This review critically examines the molecular and cellular mechanisms by which neuroinflammation contributes to AD progression, emphasizing the roles of microglial receptors such as toll-like receptors (TLRs), TREM2, and components of the NLRP3 inflammasome in regulating phagocytosis, cytokine release, and glial metabolic states. Astrocytic reactivity, particularly the shift toward neurotoxic A1 phenotypes, is explored in relation to impaired glutamate homeostasis, synaptic degradation, and blood–brain barrier dysfunction.

Further attention is given to the complex crosstalk between central and peripheral immune systems, including the influence of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α, chemokine-driven immune recruitment, complement system activation, and chronic systemic inflammation. Genetic and molecular determinants including APOE ε4, TREM2 mutations, and other immune-related risk alleles are evaluated for their impact on lipid metabolism, microglial responsiveness, Aβ clearance efficiency, and susceptibility to neurodegeneration. Additionally, emerging research on microbiome-immunity interactions, oxidative stress pathways, and metabolic dysregulation provides new insight into the interconnected nature of inflammatory and neurodegenerative processes in AD.

This review also assesses current and emerging therapeutic strategies that target neuroinflammation. These include inhibitors of inflammasome activation, cytokine-neutralizing antibodies, complement inhibitors, microglial phenotype modulators, and pharmacological agents that enhance adaptive immune regulation or promote Aβ clearance. Innovative approaches such as nanoparticle-based drug delivery, gene-editing technologies, and lifestyle-driven anti-inflammatory interventions are considered for their potential to improve treatment specificity, reduce off-target effects, and modify disease trajectory. Despite advances in understanding immune mechanisms in AD, challenges remain regarding the timing, safety, and individualized application of immunomodulatory therapies.

Overall, delineating the multifaceted role of neuroinflammation in AD offers essential insights for developing more effective disease-modifying treatments. Integrating mechanistic understanding with translational therapeutic strategies may enable more precise modulation of immune pathways to slow or prevent neurodegeneration and improve clinical outcomes in Alzheimer's disease.

Keywords: Alzheimer's disease; neuroinflammation; microglial activation; astrocyte reactivity; amyloid-β; tau pathology; cytokines; chemokines; NLRP3 inflammasome; TREM2; complement system; neuroimmune interactions; APOE ε4; neurodegeneration; therapeutic immunomodulation.

1. Introduction

Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder that accounts for the majority of dementia cases globally. With the continual increase in life expectancy, the prevalence of AD is expected to rise substantially in the coming decades, presenting significant challenges for public health systems, caregivers, and biomedical research (1). Clinically, AD manifests as persistent memory impairment, deterioration of executive and behavioral functions, and eventual decline in basic physiological and cognitive abilities. Pathologically, AD has long been characterized by two primary hallmarks: extracellular amyloid-β (Aβ) plaque deposition and the intracellular accumulation of hyperphosphorylated tau protein forming neurofibrillary tangles (NFTs) (2). However, it is now evident that these classical lesions represent only one dimension of a broader and more intricate pathophysiological network.

In recent years, neuroinflammation has emerged as a critical factor in AD, influencing both the initiation and progression of the disease. Historically regarded as a secondary response to neuronal injury, inflammation in AD is now understood to act as a primary driver of neurodegeneration (3). The central nervous system (CNS) possesses a highly specialized and regulated immune environment, dominated by resident immune cells such as microglia and astrocytes, as well as components of the complement system, cytokine networks, and peripheral immune influences. Under physiological conditions, these cells maintain tissue homeostasis, support synaptic pruning, regulate neurovascular interactions, and clear cellular debris (4). In AD, however, persistent activation of these immune elements leads to chronic inflammatory states that disrupt neuronal function, alter glial phenotypes, impair synaptic connectivity, and compromise blood–brain barrier functionality.

Microglia, the principal immune cells of the CNS, play a dual role in AD pathology. Early in disease, microglial activation may facilitate the clearance of Aβ aggregates through phagocytosis and enzymatic degradation. Yet chronic exposure to Aβ, tau species, reactive oxygen species, and metabolic stress eventually shifts microglia toward a sustained pro-inflammatory phenotype (5). This transformation is characterized by upregulation of pattern-recognition receptors such as toll-like receptors (TLRs), triggering receptor expressed on myeloid cells 2 (TREM2), and components of the NLRP3 inflammasome. Activation of these pathways leads to the release of inflammatory cytokines, including IL-1β, IL-6, and TNF-α, which potentiate synaptic loss, impair neuronal metabolic activity, and propagate further immune activation in a self-amplifying cycle.

Astrocytes, another major glial population, also undergo profound phenotypic changes during AD progression. Reactive astrocytes shift toward neurotoxic profiles associated with impaired glutamate uptake, dysregulation of ion homeostasis, altered metabolic support to neurons, and contributions to blood–brain barrier degradation (6). Together with microglia, astrocytes participate actively in complement system activation, particularly through the C1q-C3 axis, which has been implicated in excessive synaptic pruning and neuronal vulnerability.

Genetic evidence further reinforces the centrality of neuroinflammation in AD. Genome-wide association studies have identified numerous immune-related risk genes, most notably APOE ε4, TREM2, CD33, CR1, and PLCG2. These genes regulate lipid transport, microglial phagocytosis, complement activation, and immune signaling pathways. Variants in these genes alter glial functionality, compromise Aβ clearance, enhance susceptibility to inflammation, and significantly modify disease risk (7). Such findings support the hypothesis that immune dysregulation is not merely reactive but contributes directly to pathogenic cascades that precede cognitive symptoms by decades.

Beyond genetic and molecular factors, systemic influences such as metabolic dysfunction, chronic peripheral inflammation, microbial dysbiosis, and vascular pathology further exacerbate neuroinflammatory responses. Conditions including obesity, hypertension, diabetes mellitus, and chronic infections elevate circulating inflammatory mediators and compromise blood–brain barrier integrity (8). This allows peripheral immune

molecules and cells to interact with CNS compartments, amplifying neuroinflammation and thereby accelerating AD progression.

As the role of neuroinflammation becomes more clearly defined, therapeutic strategies targeting inflammatory pathways have gained increasing prominence. Immunomodulatory approaches aim to restore microglial homeostasis, inhibit inflammasome activation, neutralize pro-inflammatory cytokines, regulate complement activation, and modulate glial phenotypes (9). In addition, innovative techniques such as nanoparticle-based drug delivery, gene editing, metabolic reprogramming, neuroprotective lifestyle interventions, and integrated multi-target therapies are being explored to counteract the multifactorial nature of AD-associated inflammation.

Despite these advances, numerous challenges remain, including identifying optimal intervention windows, characterizing patient-specific inflammatory profiles, and distinguishing beneficial immune responses from pathological ones. Therefore, a thorough understanding of the molecular mechanisms governing neuroinflammatory processes is essential for the development of effective disease-modifying interventions.

This paper aims to provide a comprehensive examination of neuroinflammation in Alzheimer's disease by analyzing its molecular foundations, cellular contributors, systemic interactions, and potential as a therapeutic target. By synthesizing emerging findings across genetics, immunology, neurobiology, and translational research, this review highlights the indispensable role of neuroinflammation in shaping AD pathogenesis and offers direction for future therapeutic innovations.

2. Overview of Alzheimer's Disease: Pathology, Epidemiology, and Current Understanding

2.1 Epidemiology and Global Health Burden

Alzheimer's disease (AD) constitutes the predominant cause of dementia and represents a major global health challenge due to its rapidly increasing prevalence. According to epidemiological projections, the number of individuals living with AD will rise dramatically over the next several decades, driven primarily by demographic aging, increased life expectancy, and improved survival from other chronic conditions (10). The disease disproportionately affects older adults, with prevalence doubling approximately every five years after age 65. This demographic trend places tremendous strain on healthcare systems, caregiving networks, and economic resources. The societal cost of AD includes direct medical expenses, long-term institutional care, caregiver burden, and diminished quality of life for both patients and families. Low- and middle-income countries are expected to experience the steepest rise in AD cases, highlighting the need for robust global strategies in prevention, diagnosis, and management.

2.2 Clinical Features and Disease Progression

The clinical course of AD is characterized by gradual yet relentless cognitive deterioration. Early symptoms often include episodic memory deficits, impaired attention, and difficulties with learning new information. As the disease advances, deficits expand to encompass language disturbances, executive dysfunction, visuospatial disorientation, impaired judgment, and profound behavioral and psychological changes (11). Later stages are marked by severe cognitive decline, motor difficulties, loss of independence, and complete reliance on caregivers. AD progresses through distinct phases, starting with a long preclinical stage in which pathological changes accumulate silently, followed by mild cognitive impairment (MCI) due to AD, and ultimately culminating in fully developed dementia (12). Neuroimaging and biomarker research indicate that amyloid deposition, tau aggregation, and synaptic dysfunction begin more than a decade prior to clinical symptoms, underscoring the importance of early identification and preventive interventions.

2.3 Classical Pathological Hallmarks: Amyloid-β and Tau

The neuropathological signature of AD is defined by two major proteinopathies. The first hallmark is extracellular amyloid-β (Aβ) accumulation, resulting from aberrant cleavage of amyloid precursor protein (APP) by β- and γ-secretases. Soluble Aβ oligomers are considered particularly neurotoxic, interfering with synaptic signaling, impairing neuronal plasticity, and triggering oxidative stress. Over time, these oligomers aggregate into insoluble fibrils and plaques. The second hallmark is intracellular accumulation of hyperphosphorylated tau protein, which destabilizes microtubules and contributes to cytoskeletal collapse (13). Tau aggregates form neurofibrillary tangles (NFTs) that disrupt neuronal architecture, impair axonal transport, and ultimately promote neuronal death. Spatiotemporally, tau pathology correlates more strongly with cognitive impairment than amyloid burden, spreading through anatomically connected brain regions in a stereotypical pattern.

2.4 Limitations of the Amyloid–Tau Hypothesis

Despite decades of research focused on amyloid and tau, the classical amyloid cascade hypothesis does not fully account for the complexity and variability of AD. Numerous clinical trials targeting Aβ clearance have demonstrated reductions in amyloid load but minimal cognitive benefit, suggesting that amyloid may be necessary but not sufficient to drive neurodegeneration. Furthermore, amyloid plaques are frequently observed in cognitively normal older adults, raising the possibility that amyloid deposition alone does not determine clinical outcomes (14). Similarly, while tau pathology correlates with disease severity, it does not explain disease initiation or the wide spectrum of neuropathological presentations. These limitations indicate that additional processes—beyond amyloid and tau—play significant roles in AD pathogenesis and progression.

2.5 Emerging Multidimensional Understanding of AD Pathology

Contemporary AD research increasingly adopts a multidimensional framework that integrates multiple interacting mechanisms. Neuroinflammation, vascular dysfunction, mitochondrial impairment, synaptic degeneration, metabolic dysregulation, and genetic susceptibility collectively shape disease onset and trajectory. Chronic activation of microglia and astrocytes, disruption of blood–brain barrier integrity, complement-mediated synaptic elimination, and systemic immune influences have emerged as key contributors to neuronal vulnerability. Additionally, metabolic disorders such as insulin resistance, cardiovascular abnormalities, and alterations in the gut–brain axis have been linked to heightened risk and accelerated progression of AD (15). This expanded conceptualization recognizes AD as a network-based disease involving complex biological interactions rather than a singular pathology driven exclusively by amyloid and tau. A simplified schematic of these interacting inflammatory mechanisms, including microglial activation, cytokine release, complement-mediated synaptic loss, and blood–brain barrier disruption, is shown in **Figure 1**.



Figure 1 Overview of neuroinflammatory mechanisms in Alzheimer's disease, illustrating interactions among activated microglia, astrocytic A1 phenotypes, amyloid-β plaque stimulation, complement protein C3 involvement, and blood–brain barrier disruption.

3. Cellular and Molecular Basis of Neuroinflammation in Alzheimer's Disease

3.1 Definition and Physiological Role of Neuroinflammation

Neuroinflammation refers to the complex, coordinated immune response within the central nervous system (CNS) that is primarily mediated by resident glial cells, including microglia and astrocytes, as well as molecular components of the innate immune system. Under physiological conditions, neuroinflammation is tightly regulated and serves several protective functions, such as clearing cellular debris, containing infections, promoting synaptic remodeling, and maintaining homeostasis in response to injury (16). Unlike peripheral inflammation, CNS immune responses are more restricted in order to preserve neuronal integrity and prevent excessive tissue damage in the metabolically demanding brain environment. However, in Alzheimer's disease (AD), this finely balanced immune system becomes chronically dysregulated. Instead of resolving pathogenic stimuli such as amyloid-β (Aβ) and tau aggregates, prolonged neuroinflammation transforms into a maladaptive process that exacerbates neuronal dysfunction, promotes synaptic degradation, and accelerates neurodegeneration.

3.2 Microglial Activation States and Functional Transitions

Microglia are the primary immune cells of the CNS and play a central role in initiating and regulating neuroinflammatory responses in AD. In the healthy brain, microglia exist in a surveillant state, continuously monitoring the microenvironment for signs of injury or pathogenic molecules (17). Upon encountering stimuli such as Aβ oligomers, misfolded tau, or damaged neurons, microglia undergo morphological and functional transformation into activated states. Early in disease progression, microglial activation may be protective, promoting phagocytic clearance of Aβ and secretion of neurotrophic factors. However, chronic exposure to pathological stimuli induces a shift toward a pro-inflammatory phenotype characterized by the upregulation of pattern-recognition receptors such as toll-like receptors (TLRs), triggering receptor expressed on myeloid cells 2 (TREM2), and components of the NLRP3 inflammasome (18). Activation of these pathways results in the release of pro-inflammatory cytokines, reactive oxygen species, and nitric oxide, leading to neuronal injury and impaired synaptic function. Additionally, sustained microglial activation promotes a metabolic shift from oxidative phosphorylation to glycolysis, further reinforcing inflammatory signaling and reducing phagocytic efficiency.

3.3 Astrocytic Reactivity and Neurotoxic A1 Phenotypes

Astrocytes, the most abundant glial cell type in the CNS, play essential roles in synaptic support, neurotransmitter clearance, ion homeostasis, and metabolic regulation. In AD, astrocytes become reactive in response to Aβ accumulation, pro-inflammatory cytokines, and microglial signaling. Reactive astrocytes can differentiate into distinct phenotypes, including the neurotoxic A1 phenotype, which contributes to synaptic destruction, neuronal death, and the propagation of inflammatory signaling. A1 astrocytes secrete complement proteins, lose their ability to regulate glutamate uptake, and exhibit impaired metabolic support, leading to excitotoxicity and further neuronal vulnerability (19). Moreover, reactive astrocytes contribute to local oxidative stress, produce pro-inflammatory mediators, and interact synergistically with microglia to enhance chronic inflammation in AD pathology.

3.4 Molecular Mediators: Cytokines, Chemokines, and Reactive Oxygen Species

A wide range of molecular mediators orchestrates neuroinflammatory signaling in AD. Pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) are elevated in AD brains and contribute to synaptic impairment, tau hyperphosphorylation, and neuronal death. Chemokines including CCL2, CXCL10, and fractalkine regulate immune cell recruitment and microglial–neuron interactions, often amplifying inflammatory cascades (20). Additionally, reactive oxygen species (ROS) and nitric oxide (NO), produced by activated microglia and astrocytes, induce oxidative stress and mitochondrial dysfunction, further exacerbating neuronal damage. Chronic elevation of these mediators disrupts synaptic

stability, enhances tau pathology, and perpetuates the inflammatory cycle. Progressive increases in IL-1β, IL-6, and TNF-α across cognitive impairment stages further illustrate the amplification of systemic and central inflammation during AD progression, as shown in **Figure 2**.



Figure 2 Cytokine levels (IL-1β, IL-6, TNF-α) across cognitive stages from healthy controls to moderate–severe Alzheimer's disease, demonstrating progressive elevation of pro-inflammatory signaling.

3.5 Role of the Complement System in Synapse Loss

The complement system, traditionally associated with peripheral immunity, plays critical roles in CNS synaptic pruning and innate immune surveillance. In AD, aberrant activation of the complement cascade—particularly components such as C1q, C3, and C4—leads to pathological synapse elimination. Microglia recognize complement-tagged synapses and engulf them through complement receptor signaling, resulting in widespread synaptic loss and impaired neural circuitry. Several studies demonstrate that complement proteins are upregulated in early AD and localize to regions of high synaptic vulnerability, suggesting that complement-mediated pruning contributes directly to cognitive decline (21). Furthermore, interactions between complement components and reactive astrocytes accelerate inflammatory signaling and potentiate neurodegeneration.

3.6 Blood–Brain Barrier Disruption and Neurovascular Dysfunction

The blood–brain barrier (BBB) is essential for maintaining CNS homeostasis by regulating molecular and cellular exchange between the brain and peripheral circulation. In AD, BBB integrity is compromised due to endothelial dysfunction, pericyte loss, and inflammatory insults. BBB breakdown facilitates the infiltration of peripheral immune cells, circulating cytokines, and plasma proteins into the brain parenchyma, amplifying local inflammatory responses (22). Neurovascular dysfunction also disrupts cerebral blood flow regulation, impairs metabolic support for neurons, and exacerbates oxidative stress. In parallel, vascular inflammation contributes to Aβ deposition in cerebral vessels, a process known as cerebral amyloid angiopathy, which further compromises vascular stability and barrier function. Collectively, BBB disruption plays a critical role in linking systemic inflammation to central neuroinflammation and accelerating AD pathology. The close association between amyloid deposition and microglial activation, consistent with PET imaging studies, is illustrated in **Figure 3**, showing a positive correlation between amyloid PET SUVR and microglial activation indices.



Figure 3 Relationship between amyloid-β plaque burden (PET SUVR) and microglial activation, demonstrating a positive correlation between pathological protein accumulation and innate immune activation.

4. Role of Glial Cells, Cytokines, and Immune Signaling Pathways in Disease Progression

4.1 Toll-like Receptor (TLR) Signaling in Response to Amyloid and Tau

Toll-like receptors (TLRs) are a class of pattern-recognition receptors that detect pathogenic molecules and endogenous danger-associated molecular patterns. In Alzheimer's disease, TLRs expressed on microglia, astrocytes, and certain neuronal populations recognize amyloid-β (Aβ) oligomers, fibrillary Aβ, and misfolded tau species. Engagement of TLR2, TLR4, and TLR6 is particularly implicated in AD pathology. Upon ligand binding, TLRs activate downstream signaling cascades involving MyD88 and NF-κB, leading to the transcription of pro-inflammatory genes (23). Although initial TLR activation may enhance Aβ uptake and clearance, chronic stimulation results in excessive cytokine production, oxidative stress, and impaired phagocytic efficiency. Additionally, TLR-driven inflammatory responses promote tau hyperphosphorylation and aggregation, linking innate immune activation to both major proteinopathies of AD. Persistent TLR signaling thus shifts microglia from a homeostatic state to a chronic inflammatory phenotype that exacerbates neurodegeneration.

4.2 NLRP3 Inflammasome Activation and Pyroptosis

The NLRP3 inflammasome is a multi-protein complex that plays a central role in innate immunity. In AD, Aβ aggregates, fibrils, and damaged mitochondria act as potent activators of the NLRP3 inflammasome in microglia. Upon activation, NLRP3 recruits ASC and caspase-1, leading to the maturation and release of interleukin-1β (IL-1β) and interleukin-18 (IL-18), two key pro-inflammatory cytokines. Inflammasome activation can also trigger pyroptosis, a form of lytic programmed cell death associated with membrane rupture and release of inflammatory mediators. The chronic activation of NLRP3 contributes to synaptic dysfunction, enhances tau pathology, and reduces microglial clearance of Aβ. Experimental inhibition or genetic deletion of NLRP3 has been shown to decrease neuroinflammation and improve cognitive outcomes in AD models, underscoring its pivotal role in driving disease progression.

4.3 TREM2 Signaling and Microglial Phagocytic Pathways

Triggering receptor expressed on myeloid cells 2 (TREM2) is an essential regulator of microglial metabolism, phagocytosis, and survival. Genetic variants in TREM2 significantly increase the risk of Alzheimer's disease, highlighting its importance in immune homeostasis. TREM2 signaling promotes microglial transition into a

disease-associated microglia (DAM) state, which is optimized for responding to Aβ and neuronal debris. Proper TREM2 function facilitates the clearance of Aβ deposits and attenuates inflammation. However, TREM2 loss-of-function mutations impair microglial energy metabolism, reduce phagocytic capacity, and promote a pro-inflammatory environment. Furthermore, defective TREM2 signaling results in inadequate microglial clustering around plaques, leading to increased plaque toxicity, enhanced neuritic dystrophy, and accelerated neurodegeneration. Thus, TREM2 serves as a critical molecular switch that determines whether microglia act in protective or detrimental ways during AD progression.

4.4 Crosstalk Between Microglia and Astrocytes in Chronic Inflammation

Microglia and astrocytes engage in continuous bidirectional communication that shapes the inflammatory microenvironment in the AD brain. Activated microglia release cytokines such as IL-1α, TNF-α, and complement component C1q, which induce astrocytes to adopt the neurotoxic A1 phenotype. A1 astrocytes, in turn, release factors that impair synaptic function, reduce neuronal metabolic support, and promote neuronal apoptosis. Astrocytes also produce chemokines that enhance microglial recruitment and activation, creating a self-reinforcing inflammatory loop. This glial crosstalk amplifies synaptic degradation, accelerates tau propagation, and contributes to widespread neuroinflammation. Disrupting microglia–astrocyte communication pathways has emerged as a promising therapeutic strategy to mitigate chronic inflammation in AD.

4.5 Pro-inflammatory Cytokines (IL-1β, IL-6, TNF-α) in Neuronal Injury

Pro-inflammatory cytokines released by activated glial cells play a direct role in neuronal dysfunction and loss. Interleukin-1β (IL-1β) enhances tau phosphorylation, disrupts synaptic plasticity, and impairs long-term potentiation. Interleukin-6 (IL-6) contributes to metabolic disruption, excitotoxicity, and neurovascular impairment. Tumor necrosis factor-alpha (TNF-α) induces neuronal apoptosis via death receptor signaling, alters neurotransmitter balance, and disrupts synaptic communication. Chronic elevation of these cytokines not only damages neurons but also perpetuates glial activation, further amplifying inflammatory signaling. High cytokine levels correlate with disease severity, suggesting that cytokine dysregulation is a major driver of cognitive decline in AD.

4.6 Complement Cascade–Mediated Synaptic Pruning

The complement system is an essential component of innate immunity that mediates synaptic pruning during development. In Alzheimer's disease, this system becomes aberrantly reactivated. Complement proteins such as C1q and C3 localize to vulnerable synapses, tagging them for elimination by complement receptor-expressing microglia. This inappropriate pruning results in significant synaptic loss, particularly in brain regions critical for learning and memory. Complement activation also promotes inflammatory signaling, endothelial dysfunction, and propagation of glial reactivity. Mouse models lacking complement components demonstrate preserved synapses and improved cognitive performance, underscoring the detrimental impact of complement-mediated pruning in AD. Targeting complement pathways has therefore become a promising avenue for therapeutic intervention. Complement activation significantly contributes to synaptic loss, particularly in later disease stages, as shown in **Figure 4**, where complement-high conditions are associated with markedly reduced synaptic density.



Figure 4 Synaptic density in complement-high versus complement-low conditions across Alzheimer's disease stages, highlighting progressive complement-mediated synaptic loss.

5. Genetic, Environmental, and Systemic Modulators of Neuroinflammatory Responses

5.1 Genetic Risk Factors: APOE ε4, TREM2, CD33, CR1

Genetic predisposition plays a crucial role in shaping neuroinflammatory processes in Alzheimer's disease (AD). Among these, the APOE ε4 allele is the strongest genetic risk factor for late-onset AD. In addition to its established influence on amyloid-β aggregation and clearance, APOE ε4 modulates microglial lipid metabolism, enhances pro-inflammatory responses, and impairs glial ability to resolve Aβ deposits. APOE ε4 carriers exhibit heightened microglial activation and increased susceptibility to cytokine-driven toxicity, suggesting that inflammatory pathways may mediate part of the genetic risk.

TREM2 variants constitute another major category of immune-related genetic risks. Loss-of-function mutations in TREM2 impair microglial phagocytosis, disrupt lipid sensing, and compromise microglial transition into protective disease-associated states. As a result, microglia become less efficient at containing Aβ plaques and more prone to chronic pro-inflammatory signaling. CD33, a sialic acid–binding immunoglobulin-like lectin, negatively regulates microglial phagocytosis; risk-associated CD33 variants increase receptor expression, thereby reducing Aβ clearance and enhancing inflammatory responses. Complement receptor 1 (CR1), involved in complement-mediated clearance of immune complexes, also plays a crucial role. Risk alleles in CR1 enhance complement activation, promoting excessive synaptic pruning and chronic inflammation. Collectively, these genes illustrate how dysregulated immune signaling is deeply embedded in the genetic architecture of AD.

5.2 Influence of Metabolic Disorders and Systemic Inflammation

Metabolic disorders, particularly obesity, type 2 diabetes mellitus, and metabolic syndrome, significantly amplify neuroinflammatory responses in AD. Chronic metabolic dysfunction promotes the release of pro-inflammatory cytokines from adipose tissue, elevates circulating insulin and glucose levels, and induces oxidative stress (24). These systemic alterations disrupt blood–brain barrier (BBB) integrity, enabling peripheral inflammatory mediators to enter the CNS. Insulin resistance in the brain further contributes to impaired neuronal energy metabolism, tau hyperphosphorylation, and heightened glial activation. Additionally, systemic inflammatory conditions such as rheumatoid arthritis, chronic infections, and autoimmune disorders increase peripheral cytokine levels that can activate microglia and exacerbate neuroinflammation. This interplay between systemic

inflammation and CNS immune signaling suggests that AD is not merely a brain-isolated disorder but is influenced by whole-body metabolic and inflammatory states.

5.3 Role of Gut Microbiome and Peripheral Immune Activation

The gut–brain axis has emerged as a significant modulator of neuroinflammatory processes in AD. Dysbiosis, characterized by imbalances in gut microbial composition, can promote the release of inflammatory metabolites, including lipopolysaccharides (LPS), short-chain fatty acid alterations, and microbial amyloids. These metabolites can enter systemic circulation and trigger peripheral immune activation, which in turn influences microglial activity and CNS inflammation. LPS, for example, can activate TLR4 signaling both peripherally and centrally, contributing to chronic microglial activation. Additionally, disruptions in microbial diversity have been linked to increased permeability of the gut barrier, enabling translocation of inflammatory molecules that exacerbate systemic and brain inflammation. Recent research suggests that restoring gut microbial balance may have potential therapeutic benefits in reducing neuroinflammatory burden and slowing AD progression.

5.4 Vascular Dysfunction and Neuroinflammation

Vascular abnormalities play a critical role in modulating neuroinflammatory responses in Alzheimer's disease. Cerebrovascular dysfunction impairs cerebral blood flow, disrupts nutrient delivery, and compromises waste clearance pathways such as the glymphatic system. These deficits create a microenvironment conducive to Aβ accumulation and neuronal stress. The breakdown of the BBB, often driven by endothelial damage, pericyte degeneration, and chronic inflammation, allows peripheral cytokines, immune cells, and plasma proteins to infiltrate the brain parenchyma (25). This intrusion initiates and amplifies glial activation, oxidative stress, and complement activation. Cerebral amyloid angiopathy, characterized by Aβ deposition in vascular walls, further exacerbates inflammatory signaling and vascular instability. The convergence of vascular dysfunction and neuroinflammation accelerates neuronal injury and contributes to cognitive decline, suggesting that vascular health and immune regulation are deeply intertwined in AD pathogenesis.

5.5 Lifestyle and Environmental Contributors

Numerous lifestyle and environmental factors modulate neuroinflammatory responses and influence AD risk. Chronic stress and sleep disturbances elevate cortisol levels and promote glial activation, impairing neuronal repair mechanisms and accelerating amyloid and tau pathology. Diets high in saturated fats and refined sugars contribute to systemic inflammation, oxidative stress, and metabolic dysfunction, all of which enhance neuroinflammatory processes. Conversely, diets rich in antioxidants, omega-3 fatty acids, and anti-inflammatory compounds may reduce glial reactivity and improve cognitive resilience. Sedentary behavior increases inflammatory markers and reduces neurotrophic support, while physical exercise has been shown to suppress pro-inflammatory cytokine production and enhance microglial homeostasis. Environmental toxins, air pollution, and exposure to particulate matter also promote systemic and central immune activation. These findings highlight that modifiable lifestyle factors can significantly alter inflammatory pathways and may serve as targets for prevention or early intervention.

6. Therapeutic Approaches Targeting Neuroinflammation: Current Strategies and Emerging Innovations

6.1 Anti-inflammatory and Immunomodulatory Pharmacological Agents

Pharmacological agents targeting inflammatory pathways represent one of the most actively investigated therapeutic domains in Alzheimer's disease (AD). Nonsteroidal anti-inflammatory drugs (NSAIDs) were among the earliest candidates; however, their limited efficacy in clinical trials suggests that broad COX inhibition is insufficient to counteract the complex neuroinflammatory machinery in AD. More selective immunomodulatory agents, such as glucocorticoids, minocycline, and agents modulating microglial activation, have shown variable outcomes due to challenges in achieving brain-specific immune regulation. Recent research focuses on

compounds that modulate glial signaling pathways without inducing global immunosuppression. Examples include PPAR-γ agonists, which shift microglia toward anti-inflammatory metabolic states; resolvins and lipoxins that promote inflammation resolution; and small molecules that suppress NF-κB signaling. These agents aim to recalibrate immune responses rather than suppress them, reflecting a more nuanced understanding of neuroinflammation's dualistic roles.

6.2 Cytokine Inhibitors and Monoclonal Antibodies

Targeting specific pro-inflammatory cytokines offers another promising therapeutic strategy. Elevated levels of IL-1β, IL-6, and TNF-α in AD brains suggest that cytokine-driven neurotoxicity contributes significantly to disease progression. Monoclonal antibodies and receptor antagonists—such as anakinra (IL-1 receptor antagonist), tocilizumab (IL-6 receptor inhibitor), and TNF-α blockers—have been evaluated for their potential to reduce neuroinflammatory burden. While these agents have demonstrated robust anti-inflammatory effects in peripheral inflammatory diseases, translating them to AD treatment requires addressing obstacles related to blood–brain barrier penetration, timing of intervention, and risk of impairing beneficial immune functions. Early-stage studies suggest that targeting cytokine signaling may preserve synaptic integrity and reduce glial activation, but long-term efficacy and safety in AD populations remain active areas of investigation.

6.3 Inflammasome Inhibitors and Complement System Modulators

Given the central role of the NLRP3 inflammasome in propagating chronic inflammation in AD, inhibitors of inflammasome activation have gained significant attention. Small molecules such as MCC950 and other caspase-1 inhibitors have shown efficacy in preclinical studies by reducing IL-1β release, mitigating pyroptosis, and improving cognitive outcomes in AD models. Complement system modulation also represents a highly promising therapeutic avenue. Aberrant activation of complement proteins, particularly C1q and C3, drives excessive synaptic pruning by microglia. Complement inhibitors—such as C1q-blocking antibodies, C3 inhibitors, and CR3 antagonists—aim to protect synapses while reducing inflammatory signaling. Early preclinical work demonstrates preservation of neuronal connectivity and improved cognitive performance, highlighting complement modulation as a potential disease-modifying strategy. Inhibition of the NLRP3 inflammasome has been shown to reduce amyloid plaque burden, decrease IL-1β release, and improve cognitive performance in preclinical models. These therapeutic effects are demonstrated in **Figures 5A–C**.



Figure 5A. Effects of NLRP3 inhibition on amyloid plaque load. Figure 5B. Reduction of IL-1β levels following NLRP3 inhibition. Figure 5C. Improvement in cognitive performance after pharmacological NLRP3 blockade.

6.4 Microglial Phenotype Reprogramming Strategies

Instead of simply suppressing microglial activation, emerging strategies aim to reprogram microglia into protective states. This approach is based on the understanding that microglia exhibit multiple phenotypes, including homeostatic, phagocytic, and inflammatory states. Agents targeting TREM2 signaling pathways seek to enhance microglial capacity to cluster around plaques and facilitate amyloid clearance. Other approaches involve enhancing microglial lipid metabolism, promoting oxidative phosphorylation over glycolysis, and restoring homeostatic transcriptional programs using small-molecule modulators. Colony-stimulating factor 1 receptor (CSF1R) inhibitors can selectively deplete dysfunctional microglia, allowing repopulation with more functional cells. Furthermore, epigenetic modulators are being explored to shift microglial gene expression profiles toward anti-inflammatory and neuroprotective states.

6.5 Nanoparticle-Based and Gene-Editing Therapeutic Approaches

Nanotechnology offers innovative and highly targeted methods to deliver therapeutic molecules across the blood–brain barrier. Nanoparticle-based systems can transport anti-inflammatory agents, siRNAs, antisense oligonucleotides, or small molecules directly to glial cells, enhancing bioavailability while minimizing systemic side effects. Similarly, gene-editing tools such as CRISPR-Cas9 hold potential for correcting mutations in immune-related genes such as TREM2 or APOE, reprogramming glial function, or suppressing inflammatory gene expression. Viral vector–mediated gene delivery and lipid nanoparticle–based systems are currently under investigation for their ability to modulate microglial pathways with high precision. Although these approaches remain largely experimental, they represent transformative possibilities for disease modification in AD.

6.6 Lifestyle Modification and Multi-Target Intervention Strategies

Lifestyle factors significantly influence neuroinflammatory processes, and interventions targeting these factors offer non-invasive, accessible therapeutic options. Regular physical exercise has been shown to reduce pro-inflammatory cytokines, enhance neurotrophic factor expression, support microglial homeostasis, and improve synaptic plasticity. Dietary interventions, including adherence to Mediterranean or ketogenic diets, can reduce systemic inflammation, improve metabolic function, and modulate gut microbiome composition, thereby indirectly influencing neuroinflammatory pathways. Sleep optimization, stress reduction, and avoidance of environmental toxins further contribute to neuroprotection. Given the multifactorial nature of AD, multi-target strategies combining lifestyle interventions with pharmacologic or biological therapies may offer synergistic benefits. This integrated approach acknowledges that modifying neuroinflammation requires simultaneous targeting of central, systemic, metabolic, and environmental contributors.

7. Challenges, Future Directions, and Implications for Disease-Modifying Therapies

7.1 Complexity and Heterogeneity of Inflammatory Responses

One of the foremost challenges in targeting neuroinflammation in Alzheimer's disease (AD) is the inherent complexity and heterogeneity of immune responses across individuals, disease stages, and brain regions. Neuroinflammation is not a uniform phenomenon; it encompasses diverse molecular pathways, glial activation states, and interactions with systemic immune signals. Microglia, for instance, exhibit varying phenotypes ranging from protective and phagocytic to highly pro-inflammatory states, depending on the microenvironmental context. Astrocytes similarly display a spectrum of reactive profiles, with some supporting neuronal survival and others promoting neurotoxicity. Moreover, factors such as age, genetic background, comorbidities, and environmental exposures shape the inflammatory landscape differently for each person. This multidimensional complexity complicates the development of interventions that can effectively modulate pathological inflammation without disrupting physiological immune functions necessary for neural homeostasis.

7.2 Timing and Specificity of Therapeutic Intervention

The success of anti-inflammatory therapies depends critically on the timing and specificity of intervention. Neuroinflammatory processes begin decades before the onset of clinical symptoms, suggesting that therapeutic windows may occur much earlier than traditionally recognized. Interventions applied too late—when extensive neuronal loss has already occurred—are unlikely to yield substantial clinical benefit. At the same time, suppressing inflammation prematurely or non-selectively may hinder beneficial immune responses required for clearing amyloid-β, repairing tissue damage, and maintaining synaptic integrity. Achieving therapeutic precision requires a deep understanding of when specific inflammatory pathways shift from adaptive to maladaptive. Furthermore, regional specificity within the brain may be crucial, as certain circuits may be more vulnerable to inflammatory damage than others. Designing therapies that accurately target pathological inflammatory signatures without compromising essential immune functions remains a significant scientific and clinical challenge.

7.3 Balancing Beneficial Versus Detrimental Immune Activity

A major obstacle in developing disease-modifying therapies is the need to distinguish between protective and detrimental aspects of neuroinflammation. Acute, regulated immune activation can facilitate amyloid clearance, promote neuronal repair, and restore tissue homeostasis. In contrast, chronic and dysregulated inflammation leads to synaptic loss, mitochondrial dysfunction, tau propagation, and neuronal death. Many inflammatory mediators, including cytokines and complement proteins, have dual roles that depend on concentration, timing, and cellular context. Over-suppression of microglial or astrocytic responses may therefore impede essential neuroprotective processes. A central challenge moving forward is the development of therapeutic strategies that recalibrate rather than eliminate immune activity—promoting a shift toward homeostatic glial states while inhibiting harmful inflammatory cascades. Achieving this balance requires detailed mapping of immune cell states and molecular signatures throughout AD progression.

7.4 Integration of Personalized Medicine with Biomarker-Based Stratification

Given the heterogeneity of neuroinflammatory mechanisms, individualized therapeutic approaches are essential. Advances in biomarker development—including cerebrospinal fluid (CSF) markers, plasma-based inflammatory signatures, neuroimaging modalities (PET, MRI), and genetic profiling—allow for more precise characterization of inflammatory states in AD. These biomarkers can identify patients who may benefit from specific immunomodulatory interventions, predict treatment response, and monitor therapeutic outcomes. Integrating patient-specific factors such as APOE genotype, TREM2 variants, metabolic status, and comorbid inflammatory conditions can further refine treatment strategies. Personalized medicine frameworks will be increasingly important for designing clinical trials that stratify participants based on molecular subtypes of AD rather than relying on broad clinical diagnoses. Such stratification increases the likelihood of identifying effective therapies and accelerates the translation of targeted interventions into clinical practice.

7.5 Future Research Priorities and Translational Considerations

Future research must focus on elucidating the precise mechanisms that govern the transition from adaptive to maladaptive neuroinflammation, with a particular emphasis on cell-specific and pathway-specific regulation. Advanced technologies such as single-cell transcriptomics, spatial proteomics, and high-resolution imaging can provide unprecedented insights into the cellular heterogeneity and dynamic progression of inflammatory responses. Additionally, preclinical models need to better reflect the complexity of human AD, incorporating comorbid metabolic, vascular, and immune factors. Translational research should prioritize the development of combination therapies that target multiple interacting pathways, such as inflammation, amyloid clearance, tau pathology, and vascular health. Regulatory and ethical considerations will also be important, particularly for emerging interventions such as gene editing, microglial reprogramming, and nanoparticle-mediated delivery

systems. Ultimately, bridging the gap between mechanistic understanding and clinical application will require interdisciplinary collaboration, improved trial design, and robust biomarker integration. These efforts are essential for advancing disease-modifying therapies that effectively address the neuroinflammatory dimension of Alzheimer's disease.

References

[1] Heneka, M. T., & Und seter, W. M., Jessen, F., et al. (2025). Neuroinflammation in Alzheimer disease. *Nature Reviews Immunology, 25*, 321-352. https://doi.org/10.1038/s41577-024-01104-7
[2] Wolfe, C. M., Fitz, N., & others. (2018). The role of APOE and TREM2 in Alzheimer disease. *Frontiers in Aging Neuroscience, 10*, Article 183. https://doi.org/10.3389/fnagi.2018.00183
[3] Liu, L., Chan, C. (2014). The role of inflammasomes in Alzheimer's disease. *Journal of Alzheimer's Disease, 42*(4), 1143-1156. https://doi.org/10.3233/JAD-140045
[4] Zhang, Z.-G., & Liu, Y. (2015). Inflammation in Alzheimer's disease and molecular genetics. *Archivum Immunologiae et Therapiae Experimentalis, 63*(4), 325-336. https://doi.org/10.1007/s00005-015-0351-0
[5] Jendresen, C., & others. (2017). TREM2 and APOE: Genetic risk factors in Alzheimer's disease. *Journal of Neuroinflammation, 14*, 31. https://doi.org/10.1186/s12974-017-0835-4
[6] McFarland, K. N., & others. (2022). Microglia in Alzheimer's disease: A key player in the inflammatory response. *Neurotherapeutics, 19*(3), 823-840. https://doi.org/10.1007/s13311-021-01179-3
[7] Tan, M. S., & others. (2013). The NLRP3 inflammasome in Alzheimer's disease. *International Journal of Alzheimer's Disease, 2013*, 406176. https://doi.org/10.1155/2013/406176
[8] Choo, X. Y., & others. (2013). Neuroinflammation and copper in Alzheimer's disease. *BioMed Research International, 2013*, 145345. https://doi.org/10.1155/2013/145345
[9] Xie, L., & others. (2015). IL-1β and the NF-κB and MAPK pathways in Alzheimer's disease. *Molecular Medicine Reports, 11*(5), 3279-3286. https://doi.org/10.3892/mmr.2015.3183
[10] Griciuc, A., & others. (2021). The role of innate immune genes in Alzheimer's disease. *Current Opinion in Neurology, 34*(2), 171-178. https://doi.org/10.1097/WCO.0000000000000961
[11] Ajoolabady, A., & others. (2025). Dual role of microglia in neuroinflammation and neurodegeneration: Implications for Alzheimer's disease. *Brain Pathology* (forthcoming).
[12] Long, C., Fritts, A., Broadway, J., Brawman-Mintzer, O., & Mintzer, J. (2025). Neuroinflammation: A driving force in the onset and progression of Alzheimer's disease. *Journal of Clinical Medicine, 14*(2), 331. *https://doi.org/10.3390/jcm14020331*
[13] Heneka, M. T., Golenbock, D. T., & Latz, E. (2015). Innate immunity in Alzheimer's disease. *Nature Immunology, 16*(3), 229-236. *https://doi.org/10.1038/ni.3102*
[14] Saco, T., & others. (2014). Inflammasome: A new trigger of Alzheimer's disease. *Frontiers in Aging Neuroscience, 6*, 80. https://doi.org/10.3389/fnagi.2014.00080
[15] Tian, C., & others. (2025). Understanding monocyte-driven neuroinflammation in Alzheimer's disease. *Science Advances, 11*(35), eadu2708. https://doi.org/10.1126/sciadv.adu2708
[16] Zhang, W., & others. (2023). Role of neuroinflammation in neurodegeneration: A comprehensive review. *Signal Transduction and Targeted Therapy, 8*, 289. https://doi.org/10.1038/s41392-023-01486-5
[17] Xie, Y., & Yu, Y. (2023). Tau and neuroinflammation in Alzheimer's disease: Interplay mechanisms and clinical translation. *Journal of Neuroinflammation, 20*, 165. https://doi.org/10.1186/s12974-023-03111-0
[18] Király, M., & others. (2023). Neuroinflammation in Alzheimer's disease: Preceding the clinical onset. *Neuroscience Research, 192*, 111-122. https://doi.org/10.1016/j.neures.2023.04.004
[19] Parhizkar, S., & others. (2022). APOE mediated neuroinflammation and neurodegeneration in Alzheimer's disease. *Frontiers in Neurology, 13*, 834297. https://doi.org/10.3389/fneur.2022.834297
[20] Ajoolabady, A., & others. (2025). Review dual role of microglia in neuroinflammation and Alzheimer's disease. *Journal of Alzheimer's Disease*. (in press)

[21] Wolfe, C. M., & others. (2020). Precision medicine approaches for neuroinflammatory mechanisms in Alzheimer's disease. *Frontiers in Immunology, 11*, 456. https://doi.org/10.3389/fimmu.2020.00456

[22] McDonald, C. L., Hennessy, E., Rubio-Araiz, A., Keogh, B., McCormack, W., McGuirk, P., & Reilly, M. (2019). TLR2 inhibition attenuates amyloid accumulation and glial activation in a mouse model of Alzheimer's disease. *Brain, Behavior, and Immunity, 58*, 191-200. https://doi.org/10.1016/j.bbi.2016.08.017

[23] Hampel, H., Caraci, F., Cuello, A. C., Caruso, G., Nisticò, R., Corbo, M., Baldacci, F., Toschi, N., Garaci, F., Chiesa, P. A., … Lista, S. (2020). A path toward precision medicine for neuroinflammatory mechanisms in Alzheimer's disease. *Frontiers in Immunology, 11*, 456. https://doi.org/10.3389/fimmu.2020.00456

[24] Bronzuoli, M. R., Iacomino, A., Steardo, L., & Scuderi, C. (2016). Targeting neuroinflammation in Alzheimer's disease: A critical appraisal. *Journal of Inflammation Research, 9*, 199-208. https://doi.org/10.2147/JIR.S105458

[25] Barczuk, J., Siwecka, N., Lusa, W., Rozpędek-Kamińska, W., Kucharska, E., & Majsterek, I. (2022). Targeting NLRP3-mediated neuroinflammation in Alzheimer's disease treatment. *International Journal of Molecular Sciences, 23*(15), 8979. https://doi.org/10.3390/ijms23158979